Skip to content

伊玛提克斯

US · IMTX #3173 按市值排名 上市于 2018
6.73 -0.41 -5.74%
实时 - 追踪5344个代码 - 心跳于370秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 2.49 低于历史水平 第27百分位
5年平均 4.95 · 在Biotechnology中排名第262/513
市盈率 -4.19 高于历史水平 第73百分位
5年平均 -1.77 · 前瞻 -3.52
市销率 23.86 高于历史水平 第90百分位
5年平均 12.08 · 前瞻 30.65 · 在Biotechnology中排名第219/387

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
伊玛提克斯 (IMTX) 1.01B -3.77 2.25 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值7.59 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算12.8%。

合理价值

Immatics NV receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 2% discount to our quantitative fair value estimate of $7.59 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet increases our fair value estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 7.5, which lies in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 5.0%, for example, falls in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

经济护城河

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

伊玛提克斯 讨论区 0 条评论

发表评论